Arrowhead Pharmaceuticals Inc. has filed an application in New Zealand seeking clearance to initiate a phase I/IIa trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement-mediated renal disease, such as immunoglobulin A nephropathy (IgAN).
Axxam SpA has signed a partnership agreement with Lundbeck A/S aimed at supporting Lundbeck on early-stage drug discovery programs related to CNS indications.
Aurinia Pharmaceuticals Inc. has submitted an IND application to the FDA for AUR-200, a potential next-generation therapy for B-cell-mediated autoimmune diseases.
Researchers from Taisho Pharmaceutical Co. Ltd. have reported initial evaluation of novel pyrazolylpyridine derivatives with increased selectivity for inhibition of the 20-hydroxyeicosatetraenoic acid (20-HETE) synthase CYP4A11/4F2, to be developed as candidates for the treatment of renal fibrosis.
Researchers from Cybin Inc. presented preclinical data for the potent and selective long-acting serotonin 5-HT2A receptor agonist, CYB-210010, as potential therapeutic candidate for the treatment of neurological disorders.
Equillium Inc. has announced that it intends to advance EQ-302, a preclinical orally delivered multi-cytokine inhibitor of IL-15 and IL-21, in place of further clinical development of EQ-102.
Irlab Therapeutics AB has completed all preclinical studies and development work with IRL-757 prior to entry to the clinic. IRL-757 is being developed as a once-daily oral treatment for apathy in Parkinson’s disease and other neurological disorders.
Researchers from Blueprint Medicines Corp. presented data from a study that aimed to assess the effects of combining cyclin-dependent kinase 2 (CDK2) inhibitor BLU-222 with CDK4/6 inhibitors, such as palbociclib or ribociclib, to overcome CDK4/6 inhibitor resistance in HR-positive/HER2-negative breast cancer.
In an article published on Dec. 18, 2023, in Nature, researchers from the Centre for Genomic Regulation in Barcelona (Spain) and Wellcome Sanger Institute in Hinxton (U.K.) reported achieving a milestone regarding KRAS targeting in cancer. The team quantified the impact of >26,000 KRAS variants and how these mutations affected protein folding and its interaction with the six main effectors – RAF1, PIK3CG, RALGDS, SOS1, K27 and K55.
RSS
